Key result
The CoreValve transcatheter self-expandable aortic bioprosthesis has been used in over 35,000 high-risk patients with severe symptomatic aortic stenosis, showing excellent results up to 4 years.
The CoreValve transcatheter aortic bioprosthesis provides an effective treatment option for patients with severe symptomatic aortic stenosis at extreme surgical risk.
Supports CoreValve TAVR in extreme-risk aortic stenosis; leaves open durability and randomized confirmation beyond 4 years.
Transcatheter aortic valve implantation has been designed to treat patients affected by severe symptomatic aortic stenosis considered extremely high risk for surgical aortic valve replacement. The CoreValve® (Medtronic Inc., MN, USA) is a multilevel self-expanding and fully radiopaque nitinol frame with a diamond cell configuration that holds a trileaflet porcine pericardial tissue valve and anchors the device in the native anatomy. CoreValve was the first percutaneous valve to be granted the CE mark for transfemoral implantation in May 2007 and the CoreValve US Pivotal Trial is actively underway. The CoreValve is available in four sizes (23, 26, 29 and 31 mm) to serve a broad range of patients' annulus from 18 to 29 mm. All the valves fit into an 18-Fr size catheter. Currently, more than 35,000 patients have been treated in more than 60 countries worldwide from the femoral artery, the axillary artery and, more recently, from a direct aortic approach, with excellent results up to 4-year follow-up.
No takes yet. Share an insight, caveat, or question.
Bruschi et al. (2013) conducted a review in Severe symptomatic aortic stenosis (n=35,000). CoreValve transcatheter self-expandable aortic bioprosthesis was evaluated. The CoreValve transcatheter self-expandable aortic bioprosthesis has been used in over 35,000 high-risk patients with severe symptomatic aortic stenosis, showing excellent results up to 4 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: